Business Context and Reporting Period
This Form 10-QSB covers the quarterly period ended September 30, 2004, for Orthodontix, Inc. (Note: The input metadata referenced "Protalix Biotherapeutics, Inc.", but the filing text explicitly identifies the issuer as Orthodontix, Inc.). The Company is a shell entity with no current operating revenues, devoting its resources to seeking a merger or acquisition with an operating business in sectors such as aircraft maintenance, health care, or financial services.
Key Financial Metrics
| Metric | Q3 2004 (3 Months) | YTD 2004 (9 Months) | YTD 2003 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(43,290) | $(128,526) | $(94,527) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.04) | $(0.03) |
| Cash and Cash Equivalents | $579,065 (as of 9/30/04) | N/A | |
| Total Liabilities | $61,284 (as of 9/30/04) | N/A | |
| Stockholders' Equity | $526,906 (as of 9/30/04) | N/A |
Cash Flow (9 Months Ended Sept 30, 2004): Net cash used in operating activities was $(152,773). Net cash provided by investing activities was $552,359, primarily due to the redemption of investments. The net increase in cash for the period was $399,586.
Material Changes vs. Prior Period
- Net Loss Increase: The net loss for the nine months ended September 30, 2004, increased to $128,526 compared to $94,527 in the same period in 2003. This is primarily driven by higher general and administrative expenses ($133,475 in 2004 vs. $94,280 in 2003).
- Liquidity Improvement: Cash and cash equivalents increased significantly from $179,479 at December 31, 2003, to $579,065 at September 30, 2004. This increase was fueled by the redemption of $552,359 in investments.
- Liabilities: Total current liabilities decreased from $78,823 at year-end 2003 to $61,284 at September 30, 2004.
Outlook, Risks, and Management Commentary
Plan of Operation: Management intends to continue seeking a business combination. The Company has no contractual commitment to any specific acquisition. It plans to utilize common stock, cash on hand, or other funding sources to effect a transaction.
Liquidity: Management believes current operating funds are sufficient to cover cash expenses for at least the next twelve months.
Risks and Contingencies:
- No Revenue: The Company does not expect to generate operating revenues or net income until a business combination is consummated.
- Acquisition Uncertainty: There are no assurances that the Company will enter into a transaction in the near term, on favorable terms, or that the combined entity will be profitable.
- Forward-Looking Statements: Actual results may differ materially due to the inability to consummate an acquisition or manage a combined business.
Controls and Procedures: Management concluded that disclosure controls and procedures were effective as of September 30, 2004, with no significant changes in internal control over financial reporting.
Investor Verification Checklist
- Shell Status: Verify the Company has no active operations and relies entirely on a future merger for revenue.
- Cash Runway: Confirm the $579,065 cash balance is sufficient to sustain operations for the projected 12-month period without additional financing.
- Share Count: Note the outstanding common stock is 2,915,428 shares; verify if any dilution is planned for a future acquisition.
- Accumulated Deficit: Review the accumulated deficit of $(3,706,207) to understand the historical capital consumption.
- Investment Redemption: Understand that the recent cash increase was due to the liquidation of existing investments ($552,359), not operational cash generation.